David S. Geldmacher, MD
Harrison Distinguished Teaching Associate Professor of Neurology
University of Virginia School of Medicine
Department of Neurology
University of Virginia Health System
Lori A. Daiello PharmD, BCPP
Post-Doctoral Dementia Research Fellow
Brown University Medical School and
Rhode Island Hospital
Alzheimer’s Disease and Memory Disorders Center
Providence, Rhode Island
THIS PROGRAM WAS ORIGINALLY PRESENTED AS A LIVE AUDIOCONFERENCE BEGINNING ON October 6, 2008. IF YOU RECEIVED CREDIT FOR PARTICIPATING IN THE AUDIOCONFERENCE, YOU ARE NOT ELIGIBLE TO RECEIVE CREDIT FOR THIS ONLINE ACTIVITY.
Alzheimer’s disease (AD) is an irreversible, progressive brain disorder that gradually destroys a person’s cognitive abilities. Currently, 4.5 million people in the United States are estimated to suffer from AD. With the first of the Baby Boomer Generation turning 65 in 2011, the prevalence of the disease will increase dramatically. By 2050, it is projected that there will be between 13.2 million and 16 million individuals with AD.
Along with deterioration of cognitive function, nearly all individuals affected by AD also experience behavioral and neuropsychiatric disturbances, such as anxiety, depression, agitation, delusions, and hallucinations. These symptoms challenge and frustrate caregivers and often result in patients being sent to long-term care centers. In most nursing homes, up to 70% of residents have AD, and up to 90% of those affected by the disease have one or more behavioral problems.
Although there is no cure for AD, there are a number of specific therapies available to help control the cognitive and behavioral symptoms of the disease. By selecting appropriate treatment plans for AD, providers of long-term care can optimize medical management to delay cognitive and functional decline, manage behavioral and neuropsychiatric symptoms, and reduce polypharmacy.
Improving the Management of Alzheimer’s Disease in Residential Care will discuss how long-term care providers can formulate appropriate treatment plans for AD and other dementias and describe therapies that manage behavioral symptoms and decrease the use of psychotropic drugs. Additionally, this program will identify common side effects associated with cholinesterase inhibitor and NMDA receptor antagonist therapy and discuss the influence various formulations of these drugs have on adherence and adverse effect profiles. Target Audience
This program has been developed specifically for LTC consultant pharmacists, medical directors, physicians, VA pharmacists, nurse practitioners, and nurses who care for patients with Alzheimer’s Disease.
Upon completion of this educational activity, the participant should be able to:
Review appropriate treatment plans for Alzheimer’s disease and other dementias
Define a comprehensive treatment care plan for Alzheimer’s disease to manage behavior and decrease the use of psychotropic drugs
Describe methods to manage common side effects associated with cholinesterase inhibitor and NMDA receptor antagonist monotherapy and combination therapy
Discuss how the various formulations of cholinesterase inhibitors may influence adherence and adverse effect profiles
It is the policy of ASCP, in accordance with the guidelines set forth by the Accreditation Council for Pharmacy Education, and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by ASCP and AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speakers’ interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
David S. Geldmacher, MD discloses that he is a member of speakers' bureaus for Eisai Inc., Novartis and Pfizer Inc, and has received research support from Eisai Inc., and Forest Laboratories, Inc.
Lori A. Daiello PharmD, BCPP discloses that she is a member of speakers' bureaus for Forest Laboratories, Inc., Eli Lilly & Co., Pfizer Inc, and Eisai Inc., is a consultant for Forest Laboratories, Inc., Eli Lilly & Co., sanofi-aventis, Pfizer Inc, and Eisai Inc., and owns stock in Myriad Pharmaceuticals. Credit Statements
Pharmacists: The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program (ACPE #203-999-08-133-H01-P) was developed by ASCP and is approved for 1.0 Contact Hour (0.1 CEU).
Nurses: NADONA/LTC is an approved provider of continuing nursing education by Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation 1087.
This program provides 1 contact hour by NADONA/LTC.
Nurse Practitioners: AKH Inc. is accredited by the American Academy of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number 030803. AKH Inc. designates this educational activity for 1 contact hour, which includes .75 pharmacology contact hour.
Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians. AKH Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
The initial release date of this activity is: October 6, 2008.
Participants must successfully complete the post test (70% or higher) and submit an evaluation to receive credit. This activity will require approximately 60 minutes to complete.
Commercial Support Statements
Supported by an educational grant from Eisai, Inc. and Pfizer Inc.
Please turn off all pop-up blockers to assure access to the educational activity.
Click on the "Start program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next main menu screen will permit you to check for or download the Flash player required to run this program. Clicking on "Click here to start the Virtual Meeting" on this screen will begin the program presentation. The menu at the top of the presentation screen will allow you to view the question and answer segment, the reference list, and the CME/CE post-test and evaluation. The program will take approximately 60 minutes to complete.
Upon completion of the program, click on the post-test button to access the post-test and program evaluation.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CPE/CE certificate/statement.